Multiple Sclerosis (MS) is a chronic, progressive neurological disease in which the immune system attacks the brain and spinal cord’s protective myelin sheath, disrupting nerve signal transmission. It affects over 2.8 million people globally and carries a significant inpatient hospital burden due to unpredictable relapses and functional decline.
Hospital admissions in MS typically arise from acute relapses, severe spasticity episodes, medication adjustments, or rapid neurological deterioration requiring close monitoring. Managing these events effectively demands structured, evidence-based protocols and coordinated multi-specialty care.
This article examines two interconnected focal points: standardized inpatient hospital protocols for spasticity management and neurological monitoring, and the emerging clinical relevance of THC-based therapies in spasticity relief. The goal is to provide clinicians, hospital administrators, and informed patients with a practical, research-grounded overview of current best practices.
Understanding Spasticity in Multiple Sclerosis: Clinical Burden and Hospital Admission Criteria
In multiple sclerosis, spasticity refers to involuntary muscle stiffness, painful spasms, and resistance to movement caused by demyelination — the progressive destruction of the protective myelin sheath surrounding nerve fibers. When upper motor neurons lose their myelin coating, signals between the brain and muscles become disrupted, producing exaggerated muscle tone and uncontrolled contractions.
Research confirms that spasticity affects approximately 60–80% of MS patients at some stage of their disease (Rizzo et al., 2004; Kister et al., 2013), making it one of the most prevalent and disabling symptoms encountered in both outpatient and inpatient settings.
Spasticity severity ranges widely — from mild morning stiffness that responds to stretching, to severe, continuous spasms that prevent walking, disrupt sleep, impair bladder control, and dramatically reduce quality of life. In advanced cases, unmanaged spasticity contributes to joint contractures, pressure ulcers, and chronic pain syndromes.
Hospital Admission Triggers
The following table outlines the most common clinical indications for inpatient MS admission related to spasticity, along with the rationale for each.
| Admission Trigger | Clinical Rationale |
|---|---|
| Spasticity crisis unresponsive to outpatient medications | Requires IV medications, close monitoring, or medication adjustment |
| Acute MS relapse with worsening neurological deficits | New demyelinating activity may intensify existing spasticity |
| Intrathecal baclofen pump complication or initiation | Demands surgical and neurological inpatient oversight |
| Falls, fractures, or secondary complications | Spasm-related injuries requiring coordinated rehabilitation |
| Diagnostic uncertainty | Inpatient workup distinguishes MS progression from mimicking conditions |
Hospitalizations for MS-related spasticity carry significant economic weight, involving longer stays, intensive physiotherapy, and multi-disciplinary coordination. Standardized, evidence-based inpatient protocols are therefore essential for improving outcomes and operational efficiency.
Hospital Protocols for Inpatient Spasticity Management in MS
Structured, standardized protocols are the backbone of effective inpatient spasticity management in multiple sclerosis. When hospitals implement clearly defined clinical pathways, they reduce treatment variability, minimize medication errors, improve patient safety, and — importantly — shorten hospital stays. Without such frameworks, spasticity care can become reactive and inconsistent, leading to preventable complications and prolonged admissions.
The table below presents a stepwise pharmacological approach to managing spasticity in hospitalized MS patients, from initial medication reassessment through to advanced interventional options.
| Step | Intervention | Goal |
|---|---|---|
| Step 1 | Reassess and optimize current oral antispasmodics (baclofen, tizanidine, dantrolene) | Restore therapeutic dosing disrupted by admission |
| Step 2 | Add or adjust adjunct medications (gabapentin, short-term benzodiazepines) | Address residual spasticity and associated pain |
| Step 3 | Consider injectable botulinum toxin for focal spasticity | Target specific overactive muscle groups |
| Step 4 | Evaluate candidacy for intrathecal baclofen (ITB) therapy | Provide sustained relief for severe, refractory cases |
| Step 5 | Document functional outcomes and pain scores using validated tools (Modified Ashworth Scale, Numerical Rating Scale) | Ensure measurable, trackable progress at every stage |
Progressing through these steps in a structured manner ensures that each patient receives appropriately escalated care based on their individual response and clinical needs.
Non-Pharmacological and Nursing Interventions
Nursing teams serve as critical frontline monitors, conducting hourly and daily spasticity assessments while maintaining structured repositioning schedules to prevent pressure injuries — a common and serious complication for immobile MS patients.
Physical and occupational therapy form the non-pharmacological foundation of inpatient care. Stretching programs, hydrotherapy, therapeutic splinting, and proper positioning collectively complement medication management and help preserve functional range of motion.
Trigger Identification and Medication Safety
Identifying spasticity triggers is equally essential within any protocol. Urinary tract infections, pressure sores, constipation, and uncontrolled pain are well-recognized aggravating factors that systematically worsen spasticity and must be screened for at admission and throughout the hospital stay.
Medication safety monitoring requires continuous vigilance. Baclofen carries significant sedation and withdrawal risks if abruptly discontinued; tizanidine demands regular hepatotoxicity surveillance. Protocols must include contingency plans for medication interruptions.
Perhaps most meaningfully, best-practice guidelines from organizations including the European MS Platform and the Consortium of MS Centers emphasize patient-centered goal setting — defining individualized functional targets such as enabling safe wheelchair transfers or improving sleep quality, rather than focusing solely on numerical scale improvements.
Neurological Monitoring in Hospitalized MS Patients: Technology, Tools, and Safety Standards
Continuous neurological monitoring during inpatient MS stays is not optional — it is essential. MS is unpredictable by nature, and hospitalization often signals a period of active disease, whether from relapse, treatment side effects, or sudden neurological decline. Structured monitoring allows clinical teams to detect subtle changes before they escalate into serious complications.
The following table outlines the primary monitoring tools used in inpatient MS care, including what each tool assesses, how frequently it is applied, and its clinical relevance.
| Monitoring Tool | What It Assesses | Frequency | Clinical Relevance |
|---|---|---|---|
| Expanded Disability Status Scale (EDSS) | Overall neurological disability level | Admission, discharge, and after interventions | Tracks relapse severity and treatment response |
| MRI (Brain & Spinal Cord) | Lesion activity, new demyelination | As clinically indicated | Confirms true relapse vs. pseudoexacerbation |
| Evoked Potential Studies | Nerve conduction in visual, sensory, and motor pathways | Per neurologist order | Detects subclinical pathway damage |
| Bladder Function Monitoring | Urinary retention, neurogenic bladder | Daily assessment | Prevents urinary tract infections and kidney damage |
| Cognitive Screening (e.g., SDMT) | Processing speed, attention | At admission and follow-up | Identifies MS-related cognitive deterioration |
| Vital Signs & Temperature Monitoring | Core body temperature, Uhthoff’s phenomenon | Every 4–8 hours | Fever worsens symptoms; prevents pseudoexacerbation misdiagnosis |
Together, these tools form a comprehensive monitoring framework that supports timely clinical decision-making throughout the inpatient stay.
Digital Tools and Healthcare Technology
Electronic health records and digital dashboards now allow real-time neurological status tracking, automatically flagging deterioration for rapid response teams. Wearable sensors monitor gait instability and tremor continuously, while AI-assisted imaging accelerates lesion identification. Telehealth integration brings specialist input directly to the bedside without delay.
Nursing Safety and Multi-Specialty Protocols
Nursing protocols prioritize fall prevention — particularly critical given MS-related proprioception loss, spasticity, and fatigue. Pressure ulcer prevention addresses risks tied to immobility and spastic posturing.
Multi-specialty consultation is triggered when needed: urology manages neurogenic bladder, pulmonology monitors respiratory function in severe cervical MS, and psychiatry addresses depression and anxiety.
Crucially, fever must be distinguished from true relapse. Even mild temperature elevation can dramatically amplify MS symptoms — a condition called pseudoexacerbation — making infection surveillance a non-negotiable component of safe inpatient MS care.
Multi-Specialty Team Coordination and Patient-Centered Care in the MS Inpatient Setting
Effective inpatient management of Multiple Sclerosis demands far more than a single physician making isolated decisions. It requires a synchronized, multi-disciplinary team (MDT) working toward shared goals — reducing relapse severity, restoring function, and preparing patients for safe discharge.
The table below identifies the key members of the inpatient MS MDT and summarizes their primary responsibilities within the care team.
| Team Member | Primary Responsibilities |
|---|---|
| Neurologist (MS Specialist) | Diagnostic leadership, disease-modifying therapy decisions, relapse management |
| Physical Therapist | Spasticity management, mobility rehabilitation, fall prevention |
| Occupational Therapist | Adaptive equipment provision, daily function assessment |
| Clinical Nurse Specialist (MS Nurse) | Medication management, patient education, protocol adherence |
| Pharmacist | Drug interaction screening, polypharmacy monitoring |
| Urologist/Continence Nurse | Neurogenic bladder assessment and management |
| Psychologist/Psychiatrist | Cognitive evaluation, emotional and mental health support |
| Social Worker/Discharge Planner | Care transitions, home support coordination |
Each team member’s contribution is integral to delivering cohesive, patient-centered care throughout the inpatient episode.
- Structured MDT Meetings and Discharge Integration: High-functioning teams conduct structured case reviews every 24 to 48 hours. These meetings assess treatment response, flag complications, and build discharge timelines early in admission — preventing costly, avoidable extended stays.
- Patient and Caregiver as Active Team Members: Shared decision-making is not optional — it is essential. Patients and caregivers contribute critical information about home environment, daily challenges, and treatment preferences. Individualized discharge planning reflecting these preferences significantly improves post-discharge adherence.
- Communication Tools That Reduce Errors: Standardized handover tools like SBAR — Situation, Background, Assessment, Recommendation — minimize miscommunication between shifts and specialties, directly improving patient safety.
- Patient Education During Admission: Before discharge, patients must understand medication schedules, spasticity triggers, self-monitoring techniques, and clear criteria for seeking emergency care. Well-educated patients experience fewer preventable readmissions.
Effective multidisciplinary care depends on structured communication, early discharge planning, active patient and caregiver participation, and clear education to support safe transitions from hospital to home.
THC and Spasticity Relief in MS: Pharmacological Basis and Clinical Evidence
Delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, has earned a legitimate place in the clinical conversation around MS spasticity — not because of recreational associations, but because of measurable neurological effects supported by structured research.
One reason for this clinical interest is the way THC acts on the spastic nervous system. THC binds to CB1 receptors distributed throughout the central nervous system, particularly in motor control regions. This binding modulates the release of key neurotransmitters — primarily GABA and glutamate — reducing the hyperexcitability of motor pathways that drives spasticity. In simpler terms, THC helps calm overactive nerve signals that cause muscles to stiffen involuntarily.
This mechanism is supported by clinical evidence. The landmark CAMS (Cannabinoids in Multiple Sclerosis) trial demonstrated subjective spasticity improvement in patients receiving cannabinoid-based treatments. Subsequent Cochrane reviews have reinforced these findings, confirming meaningful patient-reported benefit.
Building on this evidence, the most evidence-supported cannabinoid preparation is Sativex, an oromucosal spray delivering a standardized 1:1 THC:CBD ratio. Approved in over 25 countries specifically for MS spasticity, it consistently reduces patient-reported spasticity scores and shows moderate evidence for improving sleep, pain, and bladder symptoms linked to spasticity.
THC-Based vs. Conventional Antispasmodics in MS: Clinical Comparison
The following table compares nabiximols with established conventional antispasmodic therapies across key clinical parameters, including mechanism, onset, route of administration, side effects, evidence level, and hospital use.
| Category | Baclofen (Oral) | Tizanidine | Botulinum Toxin | Nabiximols (THC:CBD) |
|---|---|---|---|---|
| Mechanism | GABA-B agonist | Alpha-2 adrenergic agonist | Neuromuscular blockade | CB1 receptor modulation |
| Onset | Hours | Hours | Days to weeks | Days |
| Route | Oral | Oral | Intramuscular injection | Oromucosal spray |
| Side Effects | Sedation, weakness | Hypotension, sedation | Localized weakness | Dizziness, cognitive effects |
| Evidence Level | High | Moderate | Moderate–High | Moderate |
| Hospital Use | First-line standard | Common adjunct | Specialist-administered | Adjunct; approved formulations only |
This comparison highlights that while nabiximols occupies an adjunctive role, it offers a distinct mechanism and route of administration that may benefit patients who have not responded adequately to conventional therapies.
Hospitals must use only pharmaceutical-grade, standardized formulations — whole-plant cannabis remains too variable for controlled clinical environments. THC is not a first-line therapy but serves as a validated adjunct when conventional treatments fall short. Clinicians must monitor carefully for dizziness, sedation, and cognitive effects, particularly when combined with baclofen or benzodiazepines.
Integrating THC-Based Therapy into Hospital Inpatient Protocols: Safety, Eligibility, and Monitoring
THC-based medications approved for MS spasticity — such as nabiximols — operate within a tightly regulated prescribing framework. In most jurisdictions, their inpatient use requires prescriber certification, institutional formulary approval, and strict documentation. Hospitals must align THC administration with existing pharmacy policies before initiation or continuation during admission.
Before authorizing THC-based therapy in the inpatient setting, clinical teams should verify all of the following eligibility criteria and safety requirements.
| Eligibility Criterion | Status |
|---|---|
| Confirmed MS diagnosis with documented spasticity | ☐ Verified |
| Failure or inadequate response to ≥2 conventional antispasmodics | ☐ Verified |
| Absence of active psychosis or high-risk psychiatric history | ☐ Cleared |
| No significant drug-drug interactions with current inpatient medications | ☐ Screened |
| Patient informed consent with documented understanding of psychoactive risks | ☐ Obtained |
| Institutional formulary approval for prescribed THC preparation | ☐ Confirmed |
| Monitoring plan in place: cognitive assessment, sedation scoring, fall risk reassessment | ☐ Established |
Completing this checklist in full before initiation ensures that THC-based therapy is introduced safely and in accordance with institutional and regulatory requirements.
Inpatient THC Safety and Monitoring in MS
When initiating THC-based therapy during admission, low-dose start protocols are essential. Nursing staff must observe patients post-administration for sedation, dizziness, and cognitive changes. Co-administration with high-dose CNS depressants should be avoided due to compounding sedation risks.
For patients already established on THC therapy pre-admission, continuation decisions must therefore account for acute illness status, altered drug metabolism, and potential interactions with newly prescribed inpatient medications. Dose adjustments require clear documentation.
In this context, clinical pharmacists play a critical role in screening for interactions — particularly with sedatives, opioids, and antiepileptics common in MS polypharmacy — while ensuring proper storage and delivering patient counseling. When THC is active within the inpatient regimen, neurological monitoring intensity should increase correspondingly, consistent with protocols outlined in Section IV. Updated fall risk scoring, cognitive monitoring, and adjusted nursing supervision ratios are essential hospital safety measures that protect patient outcomes effectively.
Discharge Planning, Transition of Care, and Long-Term Spasticity Management Post-Hospitalization
Discharge planning for MS patients with spasticity is genuinely complex, largely because spasticity management doesn’t end at the hospital door — it requires careful coordination across multiple care settings. Best practice demands that planning begins at admission, not the day before discharge.
The following checklist outlines the key items that must be addressed before an MS patient with spasticity is considered ready for safe discharge.
| Checklist Item | Status |
|---|---|
| Spasticity level stabilized and functional goals met | ☐ |
| Oral medication regimen optimized; patient/caregiver educated | ☐ |
| THC-based therapy (if initiated): outpatient prescription pathway confirmed; neurologist follow-up within 2–4 weeks | ☐ |
| Physiotherapy and occupational therapy home program provided | ☐ |
| Community rehabilitation or outpatient MS clinic referral confirmed | ☐ |
| Trigger avoidance education completed (infection prevention, bladder care) | ☐ |
| Emergency re-admission criteria clearly communicated | ☐ |
| Caregiver training completed for home spasm management | ☐ |
Transition to outpatient care requires standardized handover documentation and formal shared-care agreements between hospital neurology teams and community providers, ensuring no treatment gaps occur. When THC-based therapies have been initiated during hospitalization, clear outpatient prescription pathways must be established before discharge, recognizing both their therapeutic potential and the need for ongoing monitoring of side effects and tolerability.
Evidence consistently demonstrates that structured MS discharge protocols meaningfully reduce 30-day readmission rates by addressing modifiable risk factors proactively. Scheduled post-discharge neurological reviews allow clinicians to reassess EDSS scores, refine medication regimens — including any cannabinoid preparations — and evaluate overall treatment response, ultimately supporting better long-term patient outcomes.
Conclusion
Effective inpatient management of MS-related spasticity demands structured, multi-modal hospital protocols that integrate pharmacological stepwise management, advanced neurological monitoring, and coordinated multi-disciplinary teamwork. No single intervention achieves optimal outcomes in isolation; rather, it is the systematic combination of these elements that elevates care quality.
Patient-centered principles — individualized goal setting, meaningful caregiver involvement, and thoughtful discharge planning — remain the true foundation of excellent MS inpatient care.
THC-based therapies represent a clinically supported adjunct for refractory spasticity, yet their hospital integration requires rigorous safety monitoring, regulatory compliance, and careful patient eligibility assessment. Benefits and risks must always be individually weighed.
Meanwhile, digital monitoring tools and wearable technology are steadily enhancing hospitals’ capacity to deliver precision neurological care. Continued evidence generation and institutional protocol refinement are essential to meeting the growing complexity of MS inpatient management with confidence and competence.